Clinical Trial Update: A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase II/III clinical trial evaluating Rulonilimab in combination with chemotherapy, with or without bevacizumab, as first-line treatment for persistent, recu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Chemotherapy (chemotherapy)
• Rulonilimab (Rulonilimab)

Snippet

Sponsor: Shandong New Time Pharmaceutical Co., LTD | Conditions: Cervical Cancer | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION